Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 218,800 shares, a decrease of 34.6% from the May 31st total of 334,700 shares. Based on an average daily trading volume, of 4,960,000 shares, the short-interest ratio is presently 0.0 days.

Biodexa Pharmaceuticals Stock Up 2.9 %

BDRX traded up $0.02 during trading on Friday, reaching $0.90. 89,689 shares of the company were exchanged, compared to its average volume of 317,465. The company’s 50-day moving average is $1.06 and its two-hundred day moving average is $1.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.26 and a current ratio of 1.26. Biodexa Pharmaceuticals has a 12-month low of $0.67 and a 12-month high of $9.74.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.